Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
39 participants
INTERVENTIONAL
2009-06-30
2017-06-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of Reducing Smoking in Facilitating Smoking Cessation in Adolescents - 2
NCT00158158
Evidence-Based Tobacco Cessation Strategies in Patients With Cancer
NCT02211196
Use of a Smartphone Mobile Application (App) to Enhance Smoking Cessation Treatment
NCT03519451
Web Assisted Tobacco Intervention With Community Colleges
NCT01692730
Teens Against Tobacco Use: A Model for Universal Tobacco Prevention and Youth Advocacy
NCT02443025
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To establish the feasibility of a new smoking cessation and prevention intervention including two new modules addressing alcohol use and depression.
II. Demonstrate the feasibility of a smoking prevention website.
OUTLINE: Participants are assigned to 1 of 2 arms.
ARM I: Participants who currently smoke complete a survey over 30 minutes and discuss the survey results with the counselor over 30 minutes at week 2. Participants also complete 3 internet surveys over 20 minutes.
ARM II: Participants who currently do not smoke complete a survey over 30 minutes and discuss the survey results with the counselor over 30 minutes at week 2.
After completion of study, participants are followed up at 3 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I (smoker, survey)
Participants who currently smoke complete a survey over 30 minutes and discuss the survey results with the counselor over 30 minutes at week 2. Participants also complete 3 internet surveys over 20 minutes.
Survey Administration
Complete surveys
Arm II (non-smoker, survey)
Participants who currently do not smoke complete a survey over 30 minutes and discuss the survey results with the counselor over 30 minutes at week 2.
Survey Administration
Complete surveys
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Survey Administration
Complete surveys
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* CESSATION ARM: Smoke 1 or more cigarettes a day
* CESSATION ARM: Speak and read English
* CESSATION ARM: Signed informed consent and an acknowledgement of participation requirements
* CESSATION ARM: Be enrolled in at least one class at respective campus at baseline
* CESSATION ARM: Provide current contact information
* CESSATION ARM: Have access to the Internet
* PREVENTION ARM: Student at University of Houston Central Campus or Texas A\&M University
* PREVENTION ARM: Speak and read English
* PREVENTION ARM: Signed Informed Consent and an acknowledgement of participation requirements
* PREVENTION ARM: Be enrolled in at least one class at respective campus at baseline
* PREVENTION ARM: Provide current contact information
* PREVENTION ARM: Have access to the Internet
* PREVENTION ARM: Evidence of smoking susceptibility (as defined by the Smoking Susceptibility Scale)
* CESSATION ARM: Willing to answer all survey questions on all survey instruments throughout the duration of study
* PREVENTION ARM: Willing to answer all survey questions on all survey instruments throughout the duration of study
Exclusion Criteria
* CESSATION ARM: Evidence of severe alcohol abuse (as defined by AUDIT \[Alcohol Use Disorders Identification Test\] measure)
* PREVENTION ARM: Current tobacco use
* PREVENTION ARM: Does not plan to continue as a student at their campus for at least one more year
* CESSATION ARM: Does not plan to continue as a student at their campus for at least one more year
* PREVENTION ARM: Evidence of major depressive disorder (as defined by PHQ-9 \[Patient Health Questionnaire-9\])
* PREVENTION ARM: Evidence of severe alcohol abuse (as defined by AUDIT measure)
* CESSATION ARM: Pregnancy
18 Years
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexander Prokhorov
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Texas A&M
College Station, Texas, United States
M D Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
MD Anderson Cancer Center Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2018-02552
Identifier Type: REGISTRY
Identifier Source: secondary_id
2009-0351
Identifier Type: OTHER
Identifier Source: secondary_id
2009-0351
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.